8-K Announcements
6Material company update
May 1, 2026·SEC
Material company update
Feb 10, 2026·SEC
Material company update
Dec 8, 2025·SEC
IRadimed Corporation(IRMD)Earnings, Financials & Key Ratios
IRMD•NASDAQ
52.7× P/E·Price updated Jun 19, 2026
AboutIRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.Show more
- Revenue$84M+14.4%
- EBITDA$29M+25.2%
- Net Income$22M+16.9%
- EPS (Diluted)1.75+16.7%
- Gross Margin76.75%-0.2%
- EBITDA Margin34.04%+9.4%
- Operating Margin31.2%+4.0%
- Net Margin26.82%+2.1%
- ROE24.78%+1.9%
IRMD Key Insights
IRadimed Corporation (IRMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 24.3%
- ✓Strong 5Y profit CAGR of 75.0%
- ✓FCF machine: 20.5% free cash flow margin
- ✓Strong 5Y sales CAGR of 21.5%
- ✓Healthy 5Y average net margin of 25.1%
✗Weaknesses
- ✗Expensive at 12.5x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IRMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IRMD Price & Volume
IRadimed Corporation (IRMD) stock price & volume — 10-year historical chart
Loading chart...
IRMD Growth Metrics
IRadimed Corporation (IRMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.25%
5 Years21.45%
3 Years16.28%
TTM14.81%
Profit CAGR
10 Years11.56%
5 Years75.02%
3 Years20.56%
TTM19.34%
EPS CAGR
10 Years11.3%
5 Years73.91%
3 Years19.71%
TTM18.06%
Return on Capital
10 Years18.22%
5 Years22.95%
3 Years26.83%
Last Year27.76%
IRMD Recent Earnings
IRadimed Corporation (IRMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 1, 2026Metric
Actual
Est
EPS
$0.49+16.7%
$0.42
Rev
$22M+3.1%
$21M
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$0.54+10.2%
$0.49
Rev
$23M+5.1%
$22M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.47-2.1%
$0.48
Rev
$21M-1.8%
$22M
Q3 2025
Aug 1, 2025Metric
Actual
Est
EPS
$0.49+8.9%
$0.45
Rev
$20M-0.4%
$20M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 1, 2026 | $0.49vs $0.42+16.7% | $22Mvs $21M+3.1% |
| Q1 2026 | Feb 10, 2026 | $0.54vs $0.49+10.2% | $23Mvs $22M+5.1% |
| Q4 2025 | Nov 3, 2025 | $0.47vs $0.48-2.1% | $21Mvs $22M-1.8% |
| Q3 2025 | Aug 1, 2025 | $0.49vs $0.45+8.9% | $20Mvs $20M-0.4% |
Based on last 12 quarters of dataView full earnings history →
IRMD Peer Comparison
IRadimed Corporation (IRMD) competitors in Patient monitoring and wearable diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 PRCT | 1.24B | 21.72 | -12.63 | 37.22% | -31.82% | -27.7% | 0.14 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% | ||
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 GEHC | 28.02B | 61.59 | 13.54 | 4.84% | 7.54% | 14.45% | 0.94 | |
 STE | 19.89B | 202.61 | 25.55 | 8.73% | 13.18% | 11.04% | 0.27 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 |
Compare IRMD vs Peers
IRadimed Corporation (IRMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IRMD Income Statement
IRadimed Corporation (IRMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 23.08M | 30.44M | 38.52M | 31.72M | 41.81M | 53.3M | 65.56M | 73.24M | 83.81M | 86.28M |
Revenue Growth % | -28.97% | 31.88% | 26.54% | -17.65% | 31.83% | 27.47% | 23% | 11.71% | 14.43% | 14.81% |
Cost of Goods Sold | 5.57M | 7.21M | 8.82M | 8.14M | 9.76M | 12.02M | 15.4M | 16.89M | 19.49M | 19.99M |
COGS % of Revenue | 24.13% | 23.69% | 22.89% | 25.67% | 23.35% | 22.55% | 23.5% | 23.06% | 23.25% | - |
Gross Profit | 17.51M▲ 0% | 23.23M▲ 32.6% | 29.7M▲ 27.9% | 23.57M▼ 20.6% | 32.05M▲ 36.0% | 41.28M▲ 28.8% | 50.16M▲ 21.5% | 56.35M▲ 12.3% | 64.32M▲ 14.2% | 66.3M▲ 0% |
Gross Margin % | 75.87% | 76.31% | 77.11% | 74.33% | 76.65% | 77.45% | 76.5% | 76.94% | 76.75% | 76.84% |
Gross Profit Growth % | -33.52% | 32.64% | 27.87% | -20.63% | 35.95% | 28.81% | 21.5% | 12.34% | 14.15% | - |
Operating Expenses | 16.23M | 17.22M | 21.05M | 24.33M | 22.23M | 25.65M | 30.12M | 34.39M | 38.18M | 38.34M |
OpEx % of Revenue | 70.3% | 56.58% | 54.66% | 76.71% | 53.17% | 48.13% | 45.95% | 46.95% | 45.55% | - |
Selling, General & Admin | 14.5M | 15.71M | 19.62M | 22.43M | 20.33M | 23.38M | 27.26M | 31.55M | 35.2M | 35.04M |
SG&A % of Revenue | 62.84% | 51.6% | 50.94% | 70.71% | 48.61% | 43.86% | 41.59% | 43.08% | 42% | - |
Research & Development | 1.72M | 1.52M | 1.43M | 1.9M | 1.91M | 2.28M | 2.86M | 2.83M | 2.98M | 3.31M |
R&D % of Revenue | 7.46% | 4.98% | 3.72% | 6% | 4.56% | 4.27% | 4.36% | 3.87% | 3.55% | - |
Other Operating Expenses | 111.38K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | 1.29M▲ 0% | 6M▲ 367.2% | 8.65M▲ 44.0% | -756.09K▼ 108.7% | 9.82M▲ 1398.5% | 15.63M▲ 59.2% | 20.04M▲ 28.2% | 21.96M▲ 9.6% | 26.15M▲ 19.0% | 27.95M▲ 0% |
Operating Margin % | 5.57% | 19.72% | 22.45% | -2.38% | 23.48% | 29.32% | 30.56% | 29.99% | 31.2% | 32.4% |
Operating Income Growth % | -88.23% | 367.22% | 44.03% | -108.74% | 1398.48% | 59.18% | 28.21% | 9.63% | 19.04% | - |
EBITDA | 1.73M | 6.56M | 9.89M | 582.73K | 11.22M | 16.3M | 20.8M | 22.78M | 28.53M | 29.54M |
EBITDA Margin % | 7.5% | 21.56% | 25.68% | 1.84% | 26.84% | 30.58% | 31.73% | 31.11% | 34.04% | 34.24% |
EBITDA Growth % | -84.51% | 279.33% | 50.68% | -94.11% | 1826.18% | 45.2% | 27.62% | 9.53% | 25.22% | 26.07% |
D&A (Non-Cash Add-back) | 445.27K | 559.73K | 1.24M | 1.34M | 1.41M | 670.67K | 765.18K | 817.66K | 2.38M | 1.59M |
EBIT | 1.4M | 6.2M | 8.65M | -756.09K | 9.82M | 15.63M | 20.04M | 21.96M | 26.15M | 28.96M |
Net Interest Income | 122.58K | 238.11K | 388.8K | 132.19K | 34.81K | 581.85K | 1.86M | 2.19M | 0 | 0 |
Interest Income | 122.58K | 238.11K | 388.8K | 132.19K | 34.81K | 581.85K | 1.86M | 2.19M | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 111.38K | 193.54K | 395.91K | 139.21K | 18.61K | 553.1K | 1.7M | 2.31M | 2.21M | 2.23M |
Pretax Income | 1.4M▲ 0% | 6.2M▲ 343.8% | 9.04M▲ 45.9% | -616.88K▼ 106.8% | 9.84M▲ 1694.5% | 16.18M▲ 64.5% | 21.74M▲ 34.3% | 24.28M▲ 11.7% | 28.36M▲ 16.8% | 30.18M▲ 0% |
Pretax Margin % | 6.05% | 20.36% | 23.48% | -1.94% | 23.52% | 30.36% | 33.16% | 33.14% | 33.84% | 34.98% |
Income Tax | 896.62K | -106.14K | -587.64K | -1.99M | 510.82K | 3.35M | 4.55M | 5.04M | 5.88M | 6.57M |
Effective Tax Rate % | 64.21% | -1.71% | -6.5% | 321.92% | 5.19% | 20.72% | 20.91% | 20.77% | 20.74% | 21.78% |
Net Income | 499.76K▲ 0% | 6.3M▲ 1161.3% | 9.63M▲ 52.8% | 1.37M▼ 85.8% | 9.33M▲ 581.2% | 12.83M▲ 37.6% | 17.19M▲ 34.0% | 19.23M▲ 11.9% | 22.48M▲ 16.9% | 23.61M▲ 0% |
Net Margin % | 2.17% | 20.71% | 25% | 4.32% | 22.3% | 24.07% | 26.22% | 26.26% | 26.82% | 27.36% |
Net Income Growth % | -93.07% | 1161.29% | 52.79% | -85.79% | 581.19% | 37.56% | 34.02% | 11.87% | 16.88% | 19.34% |
Net Income (Continuing) | 499.76K | 6.3M | 9.63M | 1.37M | 9.33M | 12.83M | 17.19M | 19.23M | 22.48M | 23.61M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.04▲ 0% | 0.52▲ 1200.0% | 0.78▲ 50.0% | 0.11▼ 85.9% | 0.74▲ 572.7% | 1.02▲ 37.8% | 1.35▲ 32.4% | 1.50▲ 11.1% | 1.75▲ 16.7% | 1.83▲ 0% |
EPS Growth % | -93.33% | 1200% | 50% | -85.9% | 572.73% | 37.84% | 32.35% | 11.11% | 16.67% | 18.06% |
EPS (Basic) | 0.05 | 0.52 | 0.85 | 0.11 | 0.76 | 1.02 | 1.36 | 1.52 | 1.77 | - |
Diluted Shares Outstanding | 11.72M | 12.11M | 12.28M | 12.44M | 12.59M | 12.64M | 12.72M | 12.78M | 12.85M | 12.87M |
Basic Shares Outstanding | 10.64M | 12.11M | 11.28M | 12.12M | 12.35M | 12.56M | 12.6M | 12.67M | 12.72M | 12.78M |
Dividend Payout Ratio | - | - | - | - | - | 97.9% | 76.91% | 71.11% | 66.9% | - |
IRMD Balance Sheet
IRadimed Corporation (IRMD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 35.11M | 44.54M | 58.96M | 63.74M | 76.24M | 77.49M | 76M | 75.24M | 81.2M | 86.42M |
Cash & Short-Term Investments | 26.34M | 34.38M | 46.25M | 51.98M | 62.5M | 57.96M | 49.76M | 52.23M | 51.16M | 56.37M |
Cash Only | 18.21M | 28.03M | 43.48M | 50.07M | 62M | 57.96M | 49.76M | 52.23M | 51.16M | 56.37M |
Short-Term Investments | 8.14M | 6.35M | 2.77M | 1.91M | 501.86K | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 3.78M | 4.21M | 7.29M | 4.57M | 5.14M | 13.27M | 12.22M | 10.56M | 13.67M | 0 |
Days Sales Outstanding | 59.76 | 50.48 | 69.11 | 52.65 | 44.84 | 90.9 | 68.06 | 52.61 | 59.52 | 40.66 |
Inventory | 4.21M | 4.06M | 3.64M | 3.93M | 4.3M | 5.37M | 12.82M | 10.4M | 11.62M | 0 |
Days Inventory Outstanding | 275.94 | 205.46 | 150.77 | 176.34 | 160.73 | 163.03 | 303.8 | 224.76 | 217.61 | 157.76 |
Other Current Assets | 648.88K | 526.79K | 407.8K | 771.67K | 1M | 630.96K | 1.19M | 2.05M | 4.76M | 30.05M |
Total Non-Current Assets | 3.9M | 3.9M | 7.77M | 7.33M | 6.64M | 8.02M | 16.15M | 23.08M | 27.57M | 27.97M |
Property, Plant & Equipment | 1.87M | 1.87M | 5.01M | 4.84M | 4.55M | 4.61M | 11.33M | 16.97M | 23.86M | 24.23M |
Fixed Asset Turnover | 12.35x | 16.28x | 7.69x | 6.56x | 9.19x | 11.57x | 5.79x | 4.32x | 3.51x | 3.64x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 885.5K | 832.52K | 860.09K | 960.88K | 1.12M | 2.07M | 2.52M | 3.1M | 3.38M | 3.29M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 200.2K | 109.76K | 232K | 261.99K | 201.32K | 648.67K | 181.45K | 198.91K | 239K | 456K |
Total Assets | 39.01M▲ 0% | 48.44M▲ 24.2% | 66.73M▲ 37.7% | 71.07M▲ 6.5% | 82.88M▲ 16.6% | 85.51M▲ 3.2% | 92.16M▲ 7.8% | 98.33M▲ 6.7% | 108.78M▲ 10.6% | 114.39M▲ 0% |
Asset Turnover | 0.59x | 0.63x | 0.58x | 0.45x | 0.50x | 0.62x | 0.71x | 0.74x | 0.77x | 0.78x |
Asset Growth % | 4.89% | 24.17% | 37.75% | 6.5% | 16.63% | 3.18% | 7.77% | 6.69% | 10.63% | 63.14% |
Total Current Liabilities | 4.08M | 4.69M | 5.86M | 4.92M | 6.82M | 8.55M | 16.33M | 8.51M | 10.18M | 12.12M |
Accounts Payable | 656.72K | 772.47K | 993.74K | 657.05K | 782.9K | 1.8M | 1.86M | 1.9M | 1.82M | 2.18M |
Days Payables Outstanding | 43.04 | 39.1 | 41.14 | 29.45 | 29.26 | 54.63 | 44 | 40.98 | 34.08 | 37.6 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 1.62M | 1.8M | 1.67M | 1.95M | 2.55M | 3.37M | 2.57M | 2.26M | 2.87M | 12.68M |
Other Current Liabilities | 278.61K | 315.94K | 190.18K | 236.49K | 255.31K | 94.03K | 367.46K | 268.27K | 457K | 6.54M |
Current Ratio | 8.61x | 9.50x | 10.06x | 12.96x | 11.18x | 9.06x | 4.65x | 8.84x | 7.98x | 7.13x |
Quick Ratio | 7.58x | 8.63x | 9.44x | 12.16x | 10.54x | 8.43x | 3.87x | 7.62x | 6.84x | 7.13x |
Cash Conversion Cycle | 292.66 | 216.85 | 178.74 | 199.53 | 176.3 | 199.3 | 327.85 | 236.39 | 243.05 | 160.82 |
Total Non-Current Liabilities | 2M | 1.81M | 5.35M | 4.76M | 3.88M | 3.29M | 4.41M | 2.99M | 3.98M | 3.76M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 2.72M | 2.46M | 2.21M | 1.91M | 1.62M | 1.42K | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.76M |
Total Liabilities | 6.08M | 6.5M | 11.2M | 9.68M | 10.71M | 11.84M | 20.74M | 11.51M | 14.16M | 15.88M |
Total Debt | 0 | 0 | 2.96M | 2.72M | 2.48M | 2.21M | 2.04M | 154.69K | 0 | 0 |
Net Debt | -18.21M | -28.03M | -40.53M | -47.35M | -59.52M | -55.76M | -47.72M | -52.08M | -51.16M | -56.37M |
Debt / Equity | - | - | 0.05x | 0.04x | 0.03x | 0.03x | 0.03x | 0.00x | - | 0.00x |
Debt / EBITDA | - | - | 0.30x | 4.66x | 0.22x | 0.14x | 0.10x | 0.01x | - | 0.00x |
Net Debt / EBITDA | -10.52x | -4.27x | -4.10x | -81.26x | -5.30x | -3.42x | -2.29x | -2.29x | -1.79x | -1.91x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 32.93M▲ 0% | 41.95M▲ 27.4% | 55.52M▲ 32.4% | 61.38M▲ 10.6% | 72.17M▲ 17.6% | 73.67M▲ 2.1% | 71.42M▼ 3.1% | 86.82M▲ 21.6% | 94.62M▲ 9.0% | 98.51M▲ 0% |
Equity Growth % | 3.27% | 27.38% | 32.37% | 10.55% | 17.58% | 2.08% | -3.06% | 21.56% | 8.98% | 54.62% |
Book Value per Share | 2.81 | 3.46 | 4.52 | 4.93 | 5.73 | 5.83 | 5.61 | 6.79 | 7.36 | 7.65 |
Total Shareholders' Equity | 32.93M | 41.95M | 55.52M | 61.38M | 72.17M | 73.67M | 71.42M | 86.82M | 94.62M | 98.51M |
Common Stock | 1.06K | 1.1K | 1.18K | 1.23K | 1.25K | 1.26K | 1.26K | 1.27K | 1K | 1K |
Retained Earnings | 20.36M | 26.67M | 36.3M | 37.67M | 46.99M | 47.26M | 43.26M | 56.79M | 64.23M | 67.49M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -48.91K | -42.19K | 30.37K | 37.09K | 17.01K | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IRMD Cash Flow Statement
IRadimed Corporation (IRMD) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 3.42M | 7.38M | 10.23M | 5.82M | 11.26M | 10.04M | 13.47M | 25.62M | 24.95M | 28.94M |
Operating CF Margin % | 14.8% | 24.23% | 26.57% | 18.34% | 26.92% | 18.84% | 20.54% | 34.99% | 29.76% | - |
Operating CF Growth % | -63.68% | 115.93% | 38.73% | -43.15% | 93.52% | -10.8% | 34.08% | 90.3% | -2.64% | 85.39% |
Net Income | 499.76K | 6.3M | 9.63M | 1.37M | 9.33M | 12.83M | 17.19M | 19.23M | 22.48M | 23.61M |
Depreciation & Amortization | 1.31M | 1.11M | 1.24M | 1.34M | 1.41M | 670.67K | 765.18K | 817.66K | 1.17M | 1.43M |
Stock-Based Compensation | 2.45M | 1.76M | 1.85M | 3.96M | 1.46M | 1.39M | 2.19M | 2.52M | 2.92M | 2.11M |
Deferred Taxes | -150.66K | -144.43K | -596.75K | 389.93K | 523.61K | 57.1K | -1.17M | -697.65K | 0 | 401.94K |
Other Non-Cash Items | 424.97K | 155.66K | 68.69K | -70.07K | 119.04K | 148.74K | 402.32K | -3.02K | 2.73M | 4.25M |
Working Capital Changes | -1.12M | -1.81M | -1.97M | -1.17M | -1.58M | -5.06M | -5.91M | 3.75M | -4.34M | -2.85M |
Change in Receivables | -201.59K | -446.9K | -3.11M | 2.69M | -575.54K | -8.24M | 841.91K | 1.76M | -3.03M | -680.45K |
Change in Inventory | -334.11K | -121.59K | 123.68K | -282.9K | -393.32K | -1.31M | -7.47M | 3.13M | -1.38M | -1.79M |
Change in Payables | -523.45K | 34.16K | 149.32K | -403.57K | 30.41K | 1.12M | -216.44K | -861.62K | -76K | -407.64K |
Cash from Investing | -1.02M | 1.52M | 3.2M | 246.97K | 648.24K | -1.37M | -8.01M | -8.82M | -8.42M | -4.97M |
Capital Expenditures | -824.76K | -264.67K | -368.28K | -636.75K | -482.32K | -823.02K | -7.44M | -8.01M | -7.76M | -4.6M |
CapEx % of Revenue | 3.57% | 0.87% | 0.96% | 2.01% | 1.15% | 1.54% | 11.35% | 10.93% | 9.26% | 5.33% |
Acquisitions | 49.19K | 36.35K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -49.19K | -36.35K | -117.53K | 0 | -259.43K | -1.05M | -566.66K | -811.75K | -656K | -376.23K |
Cash from Financing | -1.9M | 929.87K | 2.02M | 522.48K | 24.43K | -12.71M | -13.66M | -14.34M | -17.6M | -17.93M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | -1.82M | 0 | 0 | 1.73M | 0 | 0 | 0 | 29.62K | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | -12.56M | -13.22M | -13.68M | -15.04M | -15.43M |
Share Repurchases | -1.82M | -309.56K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -81.77K | 929.87K | 2.02M | -1.21M | 24.43K | -147.27K | -433.6K | -688.16K | -2.56M | -2.49M |
Net Change in Cash | 492.11K▲ 0% | 9.82M▲ 1895.9% | 15.45M▲ 57.3% | 6.59M▼ 57.4% | 11.93M▲ 81.1% | -4.04M▼ 133.9% | -8.2M▼ 103.0% | 2.47M▲ 130.1% | -1.07M▼ 143.5% | 6.04M▲ 0% |
Free Cash Flow | 2.59M▲ 0% | 7.11M▲ 174.4% | 9.75M▲ 37.1% | 5.18M▼ 46.8% | 10.52M▲ 103.0% | 8.17M▼ 22.3% | 5.46M▼ 33.2% | 17.62M▲ 222.8% | 17.18M▼ 2.5% | 24.1M▲ 0% |
FCF Margin % | 11.23% | 23.36% | 25.31% | 16.33% | 25.15% | 15.32% | 8.32% | 24.06% | 20.5% | 27.93% |
FCF Growth % | -67.13% | 174.45% | 37.06% | -46.85% | 102.99% | -22.33% | -33.18% | 222.83% | -2.48% | 72.16% |
FCF per Share | 0.22 | 0.59 | 0.79 | 0.42 | 0.84 | 0.65 | 0.43 | 1.38 | 1.34 | 1.87 |
FCF Conversion (FCF/Net Income) | 6.84x | 1.17x | 1.06x | 4.25x | 1.21x | 0.78x | 0.78x | 1.33x | 1.11x | 1.02x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 1.21M | 1.38M | 12K | 0 | 970K | 1.71M | 5.35M | 6.51M | 0 | 2.49M |
IRMD Key Ratios
IRadimed Corporation (IRMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 1.54% | 16.84% | 19.76% | 2.34% | 13.96% | 17.59% | 23.7% | 24.31% | 24.78% | 24.48% |
Return on Invested Capital (ROIC) | 6.67% | 31.44% | 44.86% | -3.91% | 55.18% | 76.67% | 72.21% | 56.38% | 50.16% | 49.7% |
Gross Margin | 75.87% | 76.31% | 77.11% | 74.33% | 76.65% | 77.45% | 76.5% | 76.94% | 76.75% | 76.84% |
Net Margin | 2.17% | 20.71% | 25% | 4.32% | 22.3% | 24.07% | 26.22% | 26.26% | 26.82% | 27.36% |
Debt / Equity | - | - | 0.05x | 0.04x | 0.03x | 0.03x | 0.03x | 0.00x | - | 0.00x |
FCF Conversion | 6.84x | 1.17x | 1.06x | 4.25x | 1.21x | 0.78x | 0.78x | 1.33x | 1.11x | 1.02x |
Revenue Growth | -28.97% | 31.88% | 26.54% | -17.65% | 31.83% | 27.47% | 23% | 11.71% | 14.43% | 14.81% |
Related:IRMD Dividend History·IRMD Revenue History·IRMD Price History·IRMD P/E History·IRMD Financial Ratios·IRMD Institutional Holders
IRMD SEC Filings & Documents
IRadimed Corporation (IRMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
IRMD Frequently Asked Questions
IRadimed Corporation (IRMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
IRadimed Corporation (IRMD) reported $86.3M in revenue for fiscal year 2025. This represents a 1023% increase from $7.7M in 2012.
IRadimed Corporation (IRMD) grew revenue by 14.4% over the past year. This is steady growth.
Yes, IRadimed Corporation (IRMD) is profitable, generating $23.6M in net income for fiscal year 2025 (26.8% net margin).
Dividend & Returns
Yes, IRadimed Corporation (IRMD) pays a dividend with a yield of 1.27%. This makes it attractive for income-focused investors.
IRadimed Corporation (IRMD) has a return on equity (ROE) of 24.8%. This is excellent, indicating efficient use of shareholder capital.
IRadimed Corporation (IRMD) generated $24.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.